Download Centre

Podcast

• Interview: Dr Mitchell Friedman, Director of Toxicology at Takeda Pharmaceuticals
  Interview: Dr Mitchell Friedman, Director of Toxicology at Takeda Pharmaceuticals, discusses his upcoming presentation on pre-clinical toxicity and avoiding the common mistakes in early development so as to secure patient safety and better ROI. Click here…

Articles

• Pharma IQ Article - InterMune calls off high dose trials after toxicity concerns
• Formulations for toxicology studies
  By Dr Mitchell Friedman, Director of Toxicology, Takeda Pharmaceuticals
• Research Article - FlowCytometric Detection of Pig-A Mutant Red Blood Cells Using an Erythroid-Specific Antibody
• Research Article Development of an In Vivo GeneMutation Assay Using the Endogenous Pig-A Gene
• Evaluation of Macaca mulatta as a model for genotoxicity studies
• Nirmala Bhogal, Rita Seabra and Michelle Hudson examine methods to limit the level of animal testing in clinical research
• Editorial - 21st Century Drug Development: Advances, Opportunities and Challenges
• Regulatory and scientific barriers to the safety evaluation of medical nanotechnologies
• Regulatory and scientific barriers to the safety evaluation of medical nanotechnologies
• Published MUTGEN401662 Vasily Dobrovolsky
• Drug induced mitochondrial dysfunction: An emerging model for idiosyncratic drug toxicity
  By Dr James A. Dykens, Associate Research Fellow, Drug Safety R&D, Pfizer
• Formulations for toxicology studies
  By Dr Mitchell Friedman, Director of Toxicology, Takeda Pharmaceuticals